COMMUNIQUÉS West-GlobeNewswire

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
03/08/2026
MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
QHSLab (OTCQB:USAQ) Reports Second Quarter and First Half 2026 Unaudited Financial Results
03/08/2026
Integrated Service Program (ISP) Revenue More Than Doubles Year-over-Year as Gross Margins Expand and Financing Costs Decline West Palm Beach, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the “Company”) (OTCQB: [...]
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation
03/08/2026
Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes of cardio-renal [...]
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
03/08/2026
Veteran biotech finance executive joins Cue to support the Company’s next phase of clinical and corporate growth as the company advances regulatory filing for food allergy BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue [...]
TOMI Environmental Solutions Receives EPA Registration Expanding SteraMist® for Use in Post-Harvest Agricultural Food Safety Including Cannabis and Hemp Cultivation
03/08/2026
New EPA Reg. No. 90150-4 authorizes SteraMist ® (BIT ® ) – AgriMist for use up to and including the day of harvest, opening the door to indoor, greenhouse and hydroponic cannabis and hemp operations, along with post- [...]
Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System
03/08/2026
The Company remains on track to submit its 510(k) package in calendar H2 2026, working toward planned entry into the multi-billion-dollar U.S. drug screening market NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- [...]
Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality
03/08/2026
Veteran U.S.-based CMC, supply chain, and quality leaders join Achieve as the Company continues the transition of cytisinicline finished product manufacturing to the United States SEATTLE and VANCOUVER, British Columbia [...]
CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion
03/08/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“ CDT ” or the “ Company ”) today announced that it has entered into a strategic transaction to increase its [...]
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
03/08/2026
NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company
03/08/2026
Vancouver, Canada, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
03/08/2026
CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc., (Nasdaq: TSHA) (Taysha), a clinical-stage biotechnology company focused on developing adeno-associated virus ( [...]
Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call
03/08/2026
LAKEWOOD, Colo., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality [...]
Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures
03/08/2026
Centers for Medicare & Medicaid Services (CMS) Fiscal Year 2027 Inpatient Final Rule creates three new Medicare Severity-Diagnosis Related Groups (MS-DRGs), with favorable reimbursement for Carlsmed aprevo® Lumbar [...]
Neuronetics and Jorey Chernett Announce Shared Vision
03/08/2026
Chernett Affirms Comfort with the Company’s Capital Position and Confidence in Management’s Execution Establishes Path Towards Neuronetics Board Representation MALVERN, Pa., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics [...]
Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation
03/08/2026
Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep, Relevant Experience in Life Sciences Mr. Patel and Dr. Senderowicz to Stand for Election at 2026 Annual Meeting with [...]
electroCore to Participate in Upcoming Investor Conferences
03/08/2026
ROCKAWAY, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following [...]
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
03/08/2026
Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes Initiation marks advancement of Altimmune's lead program into late-stage development following [...]
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
03/08/2026
RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 [...]
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
03/08/2026
Company to hold a conference call at 8:30 a.m. ET DURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative [...]

Pages